Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxypurinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxypurinol SCHEMBL8905476 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| Oxypurinol SCHEMBL8905886 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| Oxypurinol SCHEMBL8905835 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| Oxypurinol SCHEMBL5799552 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| Oxypurinol SCHEMBL8905877 | 0.96 | SMN1; SMN2 (0.36) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| Oxypurinol SCHEMBL9421596 | 0.89 | JAK2 (0.40) | SMN1; SMN2XDHADORA2ALMNATSHR | |
| Oxypurinol SCHEMBL9421598 | 0.89 | SMN1; SMN2 (0.36) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| Oxypurinol SCHEMBL5800677 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2CDK2LMNACYP1A2ALDH1A1 | |
| SCHEMBL1952036 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2XDHRETPI4KALRRK2 | |
| SCHEMBL888387 | 0.79 | ADORA2A (0.47) | SMN1; SMN2XDHRETPI4KALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3320 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681719-A2 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX Therapeutics Inc. (CA) | 2026-01-21 | — | — | EP | claimed |
| US-20250270302-A1 | ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS SPECIFICALLY BINDING TO GREMLIN-1 AND USES THEREOF | KANTONSSPITAL ST. GALLEN (CH) | 2025-08-28 | — | — | US | claimed |
| US-20250257123-A1 | ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS PAN-SPECIFICALLY BINDING TO GREMLIN-1 AND GREMLIN-2 AND USES THEREOF | KANTONSSPITAL ST. GALLEN (CH) | 2025-08-14 | — | — | US | claimed |
| WO-2025125896-A2 | ASSEMBLING AND DENSIFYING ACTIVATED CARBON RAW MATERIALS FOR GRANULAR ACTIVATED CARBON WITH ENHANCED UNIFORMITY AND ADSORPTIVE PROPERTIES | ARQ IP LIMITED (GB) | 2025-06-19 | — | — | WO | claimed |
| EP-4568704-A1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX Therapeutics Inc. (CA) | 2025-06-18 | — | — | EP | claimed |
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | claimed |
| WO-2025101968-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY REPEAT EXPANSION WITH NUCLEOSIDE ADMINISTRATION | REPEAT THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250099941-A1 | CARBONACEOUS MATERIALS FOR USE IN METHODS OF MANUFACTURING ACTIVATED CARBON | ARQ IP LTD (GB) | 2025-03-27 | — | — | US | claimed |
| US-20250066316-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2025-02-27 | — | — | US | claimed |
| EP-4511395-A1 | ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS PAN-SPECIFICALLY BINDING TO GREMLIN-1 AND GREMLIN-2 AND USES THEREOF | Kantonsspital St. Gallen (CH) | 2025-02-26 | — | — | EP | claimed |
| WO-1991001129-A1 | RECTALLY ADMINISTERED PHARMACEUTICAL PREPARATION | HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK (DE) | 1991-02-07 | — | — | WO | claimed |
| US-4978668-A | OXYPURINOL OR ALLOPURINOL | PURDUE RESEARCH FOUNDATION (US) | 1990-12-18 | — | — | US | claimed |
| EP-0237348-B1 | CELL PROTECTION | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-09-05 | — | — | EP | claimed |
| WO-1990006115-A2 | PREPARATIONS OF OXYPURINOL AND/OR ITS ALKALI OR ALKALINE EARTH SALTS | HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK (DE) | 1990-06-14 | — | — | WO | claimed |
| WO-1990006116-A2 | AGENTS FOR TREATING CHRONIC INFLAMMATORY DISEASES OF THE INTESTINES | HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK (DE) | 1990-06-14 | — | — | WO | claimed |
| US-4871742-A | ADMINISTERING ALLOPURINOL, OXYPURINOL, OR FLAVONOID | LABORATORIES CHAUVIN (FR) | 1989-10-03 | — | — | US | claimed |
| EP-0239289-A1 | Novel pharmaceutical combinations | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-09-30 | — | — | EP | claimed |
| EP-0237348-A1 | Cell protection | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-09-16 | — | — | EP | claimed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | claimed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | claimed |